

Pressrelease, 2024-01-30 Malmö, Sweden

aXichem Signs Letter of Intent with Silvaco, a Premium Ingredient Supplier, Regarding Marketing and Sales of aXivite in the Scandinavia

<u>aXichem AB</u> (publ), (aXichem), a developer of innovative natural analogue ingredients for the nutraceutical market, is excited to announce the company has signed a Letter of Intent (LOI) with <u>Silvaco A/S</u>, a key player in the nutraceutical, pharmaceutical, food, feed, and cosmetics industries in Scandinavia. This LOI marks the beginning of a promising collaboration aimed at introducing <u>aXivite</u>, into the Scandinavian dietary supplement market.

Silvaco A/S is a well-established, dynamic and fast-growing company, specializing in sourcing and marketing quality ingredients and raw materials for various industries. Silvaco is based in Denmark and has a strong footprint in the Scandinavian region.

"The LOI outlines the collaborative approach to commercialize aXivite, aXichem's proprietary material known for its beneficial properties in weight loss, sports nutrition, sleep aid, and gut health. Silvaco's established market presence and expertise will play a crucial role in introducing aXivite to potential customers in Scandinavia in these sectors", says Lucas Altepost, VP and VP of Sales and Marketing at aXichem.

"We look forward to a fruitful collaboration with aXichem and are excited about the opportunities this partnership will bring to the Scandinavian nutraceutical market. The partnership is expected to leverage Silvaco's extensive network and deep market knowledge, aligning perfectly with aXichem's commitment to finding the right partners in local markets", says Henrik Petersen, CEO of Silvaco.

The total market for nutrition products in the Nordic region (Denmark, Finland, Norway and Sweden) reached almost 800 million Euro in 2020 according to Euromonitor. The documented effects of aXivite and aXichem's targeted market segments are well in line with the key trends that will drive the market during the coming years as presented in the report <u>Dietary Supplement Market Outlook from 2024 to 2034</u> by Futuremarketinsights.com, such as:

- Increasing demand for probiotics and prebiotics to enhance one's digestive health.
- Growing demand for sports nutrition supplements amid surging need to improve the endurance and strength of bodybuilders & athletes.

About phenylcapsaicin and aXivite

aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, connected by a triple bond. The result is an innovative natural analog capsaicin with high purity, which in several studies has been shown to have the same health-promoting properties, as well as some unique benefits, as natural capsaicin. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.

The information was submitted, through the care of the contact person below, for publication on 30 January 2024, at 15:00 CET.

Company contact:

Torsten Helsing, CEO, aXichem AB

Phone: +46 706 863 355 Email: torsten.helsing@axichem.com

About aXichem

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bioenhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.

More information is available at www.axichem.com.